Identifying biomarkers for vascular anomalies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify non-invasive blood biomarkers for patients with various vascular anomalies, including Generalized Lymphatic Anomaly and Gorham-Stout Disease. Participants undergoing surgical procedures or sclerotherapy will have blood and tissue samples collected to analyze angiogenic factors and understand disease-causing pathways. The goal is to improve diagnosis and treatment options for these rare and potentially life-threatening conditions by avoiding invasive tissue biopsies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any patient having labs drawn as standard of care will have blood drawn for the study if consented/ assented.
* All patients who are undergoing a surgical procedure or sclerotherapy are currently consented for participation in the tissue bank.

Exclusion Criteria:

* N/A

Where it's running

• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Recruiting
• Boston Children's Hospital
  Boston, Massachusetts, United States Terminated

Study contacts

• Principal investigator: Timothy LeCras, PhD — Children's Hospital Medical Center, Cincinnati
• Study coordinator: Timothy LeCras, PhD
• Email: hvmcresearch@cchmc.org
• Phone: 5138034862

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with lymphatic anomalies

  This study is collecting information from people with lymphatic anomalies to see how these conditions affect their health and treatment over time.

  Recruiting Boston Children's Hospital · Boston, Massachusetts · NCT02399527

• Trametinib for Ras/MAPK Pathway Vascular Anomalies in Kids and Teens

  This study tests whether trametinib can help children and young people with Ras/MAPK-driven vascular anomalies.

  Recruiting Phase 2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07549646

• Alpelisib for PIK3CA/TIE-2/TEK pathway vascular anomalies

  This study tests whether alpelisib can help children and young adults with specific vascular anomalies driven by PIK3CA/TIE-2/TEK pathways.

  Recruiting Phase 2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07543822

• KP-001 vs placebo for vascular and lymphatic malformations in children and adults

  This trial tests whether KP-001 helps reduce symptoms in people aged 2 and older with common venous or lymphatic malformations or KTS/CLOVES, compared with a placebo.

  Recruiting at 5 sites Phase 3 Kaken Pharmaceutical · Charleston, South Carolina and 4 other locations · NCT07285005

• Sirolimus Withdrawal Strategies for Kaposiform Hemangioendothelioma

  This study tests how to safely stop sirolimus in people with Kaposiform Hemangioendothelioma to see if disease stays controlled after withdrawal.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07131644

• Treatment for PIK3CA-related overgrowth and malformations using RLY-2608

  This study is testing a new treatment called RLY-2608 to see if it can help adults and children with PIK3CA-related overgrowth and malformations feel better.

  Recruiting at 40 sites Phase 2 Relay Therapeutics, Inc. · Phoenix, Arizona and 39 other locations · NCT06789913

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.